Archives — September 2016 back to current month (4)
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan.
Imagin, a Better Way to Detect Bladder Cancer (09/20/2016)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes.
Regeneus Secures Government Funding for R&D (09/14/2016)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.
Three Shots on Goal in Q4/16 for DURECT Corp. (09/08/2016)
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp.
|"DRRX has received an upfront payment of $12.5 million, and is also eligible for $5 million in the event of FDA approval for Indivior's RBP-7000."|
|RP's Phase 1/2a trial for tendon repair in chronic Achilles tendinosis met its goal and established a complete safety profile at six months that showed no serious adverse events."|
|"INO announced the publication of two preclinical studies of the company's plasmid DNA-encoded monoclonal antibody constructs in treating cancer and preventing infection from a pneumonia-causing bacteria."|